ROCHE DIAGNOSTICS NORGE AS

Org. no. 987852208 · OSLO · Founded 2005 · 100 employees

Score · fiscal year 2025

69of 100

How to read this: the company is ahead of 87 % of companies in the Morning class Large in the same sector in 2025. What does this mean?

Rank in the Morning class Large: 69 of 541 · What are Morning company classes?
Place in the whole sector: 3,622 of 23,059 · Handel

Profile

Lion · Leader

High profitability, high solidity

Position against comparable companies in 2025, not a verdict on the company. Based on profitability 56 and solidity 83 out of 100 among companies in the Morning class Large in the same sector in 2025. Methodology

Against the sector

ROCHE DIAGNOSTICS NORGE AS is 19 points above the median for companies in the Morning class Large in the same sector in 2025.

Median score 50 among 541 companies.

Against companies in the Morning class Large in the same sector in 2025: operating margin 3.6% (median 2.5%) and equity ratio 53.2% (median 30.9%).

Source: Register of Company Accounts and Central Coordinating RegisterFetched 29 October 2026Report an issue
Key figures · 2025

The numbers behind the score

The numbers behind the score · 2025
MeasureCompanyMedianAhead of
Operating revenue687 MNOK1,119 MNOK
Operating margin 3.6% 2.5% 63 %
Profit margin 3.8% 2.5% shown, not part of the index
Return on assets 10.2% 10.2% 50 %
Equity ratio 53.2% 30.9% 84 %
Debt-to-equity 0.88 2.23 83 %
Current ratio 1.66 1.30 74 %
Revenue growth 9.4% 6.9% 60 %
Revenue per employee6.87 MNOK12.49 MNOK

The median and “ahead of” refer to companies in the Morning class Large in the same sector in 2025. The bar shows the share of companies the figure is ahead of.

With an index of 69, ROCHE DIAGNOSTICS NORGE AS does better than 87% of companies in the Morning class Large in the same sector (541 companies) in 2025.

Over time

Score 2023–2025

CompanyMedian0255075100202320242025
  • ROCHE DIAGNOSTICS NORGE AS
  • Median: companies in the Morning class Large in the same sector
Summary analysis

ROCHE DIAGNOSTICS NORGE AS has a score of 69 for 2025, rank 3,622 of 23,059 in the sector.

Strongest: Solidity: percentile 83 against peers, equity ratio 53.2% against a median of 30.9%. Liquidity: percentile 74 against peers, current ratio 1.66 against a median of 1.30.

No area is clearly below its peers.

Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made

Analysis · 2025

What the numbers say

ROCHE DIAGNOSTICS NORGE AS had an operating margin of 3.6% and an equity ratio of 53.2% in 2025, and ranks 3,622 of 23,059 in Handel.

From 2024 to 2025: the equity ratio rose from 43.6% to 53.2%.

This text is generated automatically from the 2025 accounts.

Estimated value · 2025

Three simple methods

The methods give between 143 MNOK and 200 MNOK.

MethodInputMultipleEstimate
P/E Net profit: 20.0 MNOK 10.0 200 MNOK
EV/EBIT Operating profit: 24.8 MNOK 8.0 missing
P/B Equity: 142.6 MNOK 1.0 143 MNOK

A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation

Indications · 2025

Worth a closer look

No rules were triggered for this year.

Indications based on the latest annual accounts from open data. Not investment or financial advice.

Financial costs were 0.8% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.

See interest rates, prices and exchange rates for the sector

Data quality

No anomalies found in the figures.

Stress test · 2022

Scenario analysis: the sector's weakest year

We have no accounts for 2022, the sector's weakest year, for this company.

The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology

Components · 2025

What the score is made of

Profitability56 weight 30%
Solidity83 weight 25%
Liquidity74 weight 15%
Growth60 weight 15%
Consistency72 weight 15%

Durability: 64 (average over 3 years)

Index version 2. Data completeness 100%: the share of the weights that had data.

2025

Questions and answers

How profitable is ROCHE DIAGNOSTICS NORGE AS?

The operating margin was 3.6% in 2025, against a median of 2.5% among companies in the Morning class Large in the same sector. Return on assets was 10.2%.

How solid is ROCHE DIAGNOSTICS NORGE AS?

The equity ratio was 53.2% in 2025 (median 30.9%). Debt-to-equity was 0.88 (median 2.23).

What is the liquidity of ROCHE DIAGNOSTICS NORGE AS like?

The current ratio was 1.66 in 2025 (median 1.30).

How does ROCHE DIAGNOSTICS NORGE AS compare in Handel?

ROCHE DIAGNOSTICS NORGE AS ranks 3,622 of 23,059 in Handel for 2025. Among companies in the Morning class Large it is number 69 of 541. Revenue changed by 9.4% from the year before.

Public contracts

Contracts awarded since 2024
8
in 7 notices (lots counted separately)
Total awarded value since 2024
431.1 MNOK
3 contracts without a stated value are not in the total.
Framework agreements
2
Left out of the total: the value is a ceiling, not actual spend.
DateBuyerNotice ValueCPV
2 July 2026 Oslo Universitetssykehus HF (hovedenhet) 77203 RH KLM PAT Immunfargemaskiner V3 418.0 MNOK (2 lots) 38000000
26 January 2026 SYKEHUSINNKJØP HF Spesialfargemaskin til Sykehuset i Vestfold HF 4.6 MNOK 33600000
7 January 2026 SYKEHUSINNKJØP HF Kontraktstildeling - Analysesystem klinisk kjemi og immunkjemi - Helse Nord 280.0 MNOK (framework) 33600000
2 September 2025 SYKEHUSINNKJØP HF Instrumenter og forbruksmateriell til pasientnær analysering av glukose 16.2 MNOK (framework) 38000000
27 June 2025 Oslo Universitetssykehus HF (hovedenhet) 77144 AK KLM MBK Instrumenter for klinisk-kjemiske analyser 8.5 MNOK 38000000
2 December 2024 SYKEHUSINNKJØP HF Instrumenter for klinisk kjemi og immunkjemi til Odda sjukehus, Helse Fonna HF value not stated 38000000
26 January 2024 Oslo Universitetssykehus HF (hovedenhet) 75634 OUS KLM MIK real-time PCR (Tuberkulose diagnostikk) ny utlysning value not stated 38900000
26 November 2020 Sykehuset Innlandet HF Helautomatiske PCR systemer for molekylær diagnostikk og påvisning av Covid-19 virus 3.1 MNOK (framework) 38000000
9 July 2020 SYKEHUSINNKJØP HF FRET PCR-instrument for levering til Helse Stavanger HF value not stated 38900000
4 January 2019 Folkehelseinstituttet Rammeavtale for prøvepreparerings-kit til forbehandling av genomisk bakterielt-DNA til helgenomsekvensering value not stated 33600000

Based on notices in Doffin. Does not show call-offs under framework agreements or purchases below the publication threshold. Values are as stated by the buyer.

Source: Doffin (DFØ), fetched 28 October 2026. Winners are matched on organisation number.

Contains data under the Norwegian licence for public data (NLOD 2.0) made available by Doffin/the Norwegian Agency for Public and Financial Management (DFØ). NLOD 2.0

From the Central Coordinating Register

Org. no.
987852208
Legal form
AS
Sector
Handel (46.460)
Morning company class
Large
Employees
100 registered 10 August 2026
Founded
20 January 2005 21 years in operation
Share capital
5.84 MNOK
Business address
Brynsengfaret 6B, 0667 OSLO
Municipality
Oslo rank 63–220 of 357 in Norway
Latest accounts filed
2025
Website
www.roche-diagnosticsnorge.no

Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre

Ownership and roles

Chief executive
Paula Aguiar Rodriguez
Chair of the board
Paula Aguiar Rodriguez
Board member
Ines Christina Vancata
Board member
Juan José Cortizo
Auditor
KPMG AS
Accountant
AZETS INSIGHT AS

Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.

Owners and shareholdings will appear here once the shareholder data extract is in place.

Coming · not built yet

Error in the data?

Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.

Report an issue

Figures last fetched 29 October 2026.

Details

Year by year · 2023–2025

Key figure202320242025Trend
Index695669
Rank4,7228,7343,622
Operating margin2.7%2.2%3.6%
Return on assets10.5%6.6%10.2%
Equity ratio45.6%43.6%53.2%
Current ratio1.551.551.66
Revenue growth–3.1%9.4%

Accounts

From the Brønnøysund Register Centre, in the company's reporting currency (NOK).

Key figure202320242025
Operating revenue608.8 MNOK628.0 MNOK687.2 MNOK
Operating profit16.5 MNOK14.0 MNOK24.8 MNOK
Profit before tax21.4 MNOK15.1 MNOK26.4 MNOK
Net profit15.7 MNOK11.2 MNOK20.0 MNOK
Financial expenses3.8 MNOK3.2 MNOK1.1 MNOK
Total assets241.3 MNOK279.9 MNOK268.1 MNOK
Current assets204.3 MNOK244.6 MNOK208.2 MNOK
Equity109.9 MNOK122.1 MNOK142.6 MNOK
Retained earnings99.9 MNOK112.1 MNOK132.6 MNOK
Total liabilities131.4 MNOK157.7 MNOK125.5 MNOK
Current liabilities131.4 MNOK157.7 MNOK125.5 MNOK

Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 29 October 2026, accounts id 7032244.

Similar companies